vs
Forestar Group Inc.（FOR）与Pacira BioSciences, Inc.（PCRX）财务数据对比。点击上方公司名可切换其他公司
Forestar Group Inc.的季度营收约是Pacira BioSciences, Inc.的1.4倍（$273.0M vs $196.9M），Forestar Group Inc.同比增速更快（9.0% vs 5.1%），Pacira BioSciences, Inc.自由现金流更多（$43.5M vs $-157.1M），过去两年Pacira BioSciences, Inc.的营收复合增速更高（8.5% vs -9.6%）
福雷斯特集团是一家住宅地块开发企业，总部位于得克萨斯州阿灵顿，业务覆盖美国21个州的51个市场。截至2020年12月31日的12个月内，该公司交付了11518块住宅地块，目前在纽约证券交易所上市，自2002年起就是美国规模最大的住宅建筑商D.R. Horton的控股子公司。
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
FOR vs PCRX — 直观对比
营收规模更大
FOR
是对方的1.4倍
$196.9M
营收增速更快
FOR
高出3.9%
5.1%
自由现金流更多
PCRX
多$200.6M
$-157.1M
两年增速更快
PCRX
近两年复合增速
-9.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $273.0M | $196.9M |
| 净利润 | $15.4M | — |
| 毛利率 | 20.1% | 79.5% |
| 营业利润率 | 7.6% | 1.2% |
| 净利率 | 5.6% | — |
| 营收同比 | 9.0% | 5.1% |
| 净利润同比 | -6.7% | — |
| 每股收益（稀释后） | $0.30 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FORPCRX
| Q4 25 | $273.0M | $196.9M | ||
| Q3 25 | $670.5M | $179.5M | ||
| Q2 25 | $390.5M | $181.1M | ||
| Q1 25 | $351.0M | $168.9M | ||
| Q4 24 | $250.4M | $187.3M | ||
| Q3 24 | $551.3M | $168.6M | ||
| Q2 24 | $318.4M | $178.0M | ||
| Q1 24 | $333.8M | $167.1M |
净利润FORPCRX
| Q4 25 | $15.4M | — | ||
| Q3 25 | $86.9M | $5.4M | ||
| Q2 25 | $32.9M | $-4.8M | ||
| Q1 25 | $31.6M | $4.8M | ||
| Q4 24 | $16.5M | — | ||
| Q3 24 | $81.5M | $-143.5M | ||
| Q2 24 | $38.7M | $18.9M | ||
| Q1 24 | $45.0M | $9.0M |
毛利率FORPCRX
| Q4 25 | 20.1% | 79.5% | ||
| Q3 25 | 22.3% | 80.9% | ||
| Q2 25 | 20.4% | 77.4% | ||
| Q1 25 | 22.6% | 79.7% | ||
| Q4 24 | 22.0% | 78.7% | ||
| Q3 24 | 23.9% | 76.9% | ||
| Q2 24 | 22.5% | 75.1% | ||
| Q1 24 | 24.9% | 71.6% |
营业利润率FORPCRX
| Q4 25 | 7.6% | 1.2% | ||
| Q3 25 | 16.9% | 3.5% | ||
| Q2 25 | 11.2% | 4.7% | ||
| Q1 25 | 11.6% | 1.2% | ||
| Q4 24 | 8.7% | 13.2% | ||
| Q3 24 | 19.7% | -82.8% | ||
| Q2 24 | 16.2% | 15.9% | ||
| Q1 24 | 17.6% | 7.9% |
净利率FORPCRX
| Q4 25 | 5.6% | — | ||
| Q3 25 | 13.0% | 3.0% | ||
| Q2 25 | 8.4% | -2.7% | ||
| Q1 25 | 9.0% | 2.8% | ||
| Q4 24 | 6.6% | — | ||
| Q3 24 | 14.8% | -85.1% | ||
| Q2 24 | 12.2% | 10.6% | ||
| Q1 24 | 13.5% | 5.4% |
每股收益（稀释后）FORPCRX
| Q4 25 | $0.30 | $0.05 | ||
| Q3 25 | $1.70 | $0.12 | ||
| Q2 25 | $0.65 | $-0.11 | ||
| Q1 25 | $0.62 | $0.10 | ||
| Q4 24 | $0.32 | $0.38 | ||
| Q3 24 | $1.59 | $-3.11 | ||
| Q2 24 | $0.76 | $0.39 | ||
| Q1 24 | $0.89 | $0.19 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $211.7M | $238.4M |
| 总债务越低越好 | $793.2M | $372.2M |
| 股东权益账面价值 | $1.8B | $693.1M |
| 总资产 | $3.2B | $1.3B |
| 负债/权益比越低杠杆越低 | 0.44× | 0.54× |
8季度趋势，按日历期对齐
现金及短期投资FORPCRX
| Q4 25 | $211.7M | $238.4M | ||
| Q3 25 | $379.2M | $246.3M | ||
| Q2 25 | $189.2M | $445.9M | ||
| Q1 25 | $174.3M | $493.6M | ||
| Q4 24 | $132.0M | $484.6M | ||
| Q3 24 | $481.2M | $453.8M | ||
| Q2 24 | $359.2M | $404.2M | ||
| Q1 24 | $416.2M | $325.9M |
总债务FORPCRX
| Q4 25 | $793.2M | $372.2M | ||
| Q3 25 | $802.7M | $376.7M | ||
| Q2 25 | $872.8M | $580.5M | ||
| Q1 25 | $872.5M | $583.4M | ||
| Q4 24 | $806.8M | $585.3M | ||
| Q3 24 | $706.4M | — | ||
| Q2 24 | $706.1M | — | ||
| Q1 24 | $705.7M | — |
股东权益FORPCRX
| Q4 25 | $1.8B | $693.1M | ||
| Q3 25 | $1.8B | $727.2M | ||
| Q2 25 | $1.7B | $757.8M | ||
| Q1 25 | $1.6B | $798.5M | ||
| Q4 24 | $1.6B | $778.3M | ||
| Q3 24 | $1.6B | $749.6M | ||
| Q2 24 | $1.5B | $879.3M | ||
| Q1 24 | $1.5B | $892.2M |
总资产FORPCRX
| Q4 25 | $3.2B | $1.3B | ||
| Q3 25 | $3.1B | $1.3B | ||
| Q2 25 | $3.1B | $1.5B | ||
| Q1 25 | $3.0B | $1.6B | ||
| Q4 24 | $3.0B | $1.6B | ||
| Q3 24 | $2.8B | $1.5B | ||
| Q2 24 | $2.7B | $1.6B | ||
| Q1 24 | $2.6B | $1.6B |
负债/权益比FORPCRX
| Q4 25 | 0.44× | 0.54× | ||
| Q3 25 | 0.45× | 0.52× | ||
| Q2 25 | 0.52× | 0.77× | ||
| Q1 25 | 0.53× | 0.73× | ||
| Q4 24 | 0.50× | 0.75× | ||
| Q3 24 | 0.44× | — | ||
| Q2 24 | 0.47× | — | ||
| Q1 24 | 0.48× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-157.0M | $43.7M |
| 自由现金流经营现金流 - 资本支出 | $-157.1M | $43.5M |
| 自由现金流率自由现金流/营收 | -57.5% | 22.1% |
| 资本支出强度资本支出/营收 | 0.0% | 0.1% |
| 现金转化率经营现金流/净利润 | -10.19× | — |
| 过去12个月自由现金流最近4个季度 | $93.0M | $136.7M |
8季度趋势，按日历期对齐
经营现金流FORPCRX
| Q4 25 | $-157.0M | $43.7M | ||
| Q3 25 | $256.3M | $60.8M | ||
| Q2 25 | $15.8M | $12.0M | ||
| Q1 25 | $-19.8M | $35.5M | ||
| Q4 24 | $-450.0M | $33.1M | ||
| Q3 24 | $119.2M | $53.9M | ||
| Q2 24 | $-61.7M | $53.2M | ||
| Q1 24 | $-59.2M | $49.1M |
自由现金流FORPCRX
| Q4 25 | $-157.1M | $43.5M | ||
| Q3 25 | $255.6M | $57.0M | ||
| Q2 25 | $15.0M | $9.3M | ||
| Q1 25 | $-20.5M | $26.9M | ||
| Q4 24 | — | $31.0M | ||
| Q3 24 | $118.4M | $49.8M | ||
| Q2 24 | $-62.3M | $51.6M | ||
| Q1 24 | $-59.8M | $46.3M |
自由现金流率FORPCRX
| Q4 25 | -57.5% | 22.1% | ||
| Q3 25 | 38.1% | 31.7% | ||
| Q2 25 | 3.8% | 5.1% | ||
| Q1 25 | -5.8% | 15.9% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | 21.5% | 29.6% | ||
| Q2 24 | -19.6% | 29.0% | ||
| Q1 24 | -17.9% | 27.7% |
资本支出强度FORPCRX
| Q4 25 | 0.0% | 0.1% | ||
| Q3 25 | 0.1% | 2.2% | ||
| Q2 25 | 0.2% | 1.5% | ||
| Q1 25 | 0.2% | 5.1% | ||
| Q4 24 | 0.0% | 1.1% | ||
| Q3 24 | 0.1% | 2.4% | ||
| Q2 24 | 0.2% | 0.9% | ||
| Q1 24 | 0.2% | 1.7% |
现金转化率FORPCRX
| Q4 25 | -10.19× | — | ||
| Q3 25 | 2.95× | 11.20× | ||
| Q2 25 | 0.48× | — | ||
| Q1 25 | -0.63× | 7.37× | ||
| Q4 24 | -27.27× | — | ||
| Q3 24 | 1.46× | — | ||
| Q2 24 | -1.59× | 2.82× | ||
| Q1 24 | -1.32× | 5.47× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FOR
| D.R.Horton Inc. | $183.8M | 67% |
| Other | $89.2M | 33% |
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
